| P50 | author | Vittorio Rosti | Q55069617 |
| P2093 | author name string | Alessandro M Vannucchi | |
| | Giovanni Barosi | |
| P2860 | cites work | Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | Q24657681 |
| | Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 |
| | CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients | Q28238474 |
| | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 |
| | Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells | Q42133453 |
| | Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. | Q43010173 |
| | Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. | Q43062274 |
| | Taxing sugar-sweetened beverages | Q43180928 |
| | JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. | Q43199526 |
| | Mutations of ASXL1 gene in myeloproliferative neoplasms. | Q43456344 |
| | Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | Q44103314 |
| | RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia | Q45054546 |
| | Decitabine is an effective treatment of idiopathic myelofibrosis | Q46169214 |
| | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject | Q46436942 |
| | Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients | Q46543499 |
| | 5-Azacitidine has limited therapeutic activity in myelofibrosis | Q46570218 |
| | Low-dose thalidomide in myelofibrosis | Q46570726 |
| | Risk factors for leukemic transformation in patients with primary myelofibrosis | Q46650489 |
| | TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients | Q46691516 |
| | Bortezomib therapy in myelofibrosis: a phase II clinical trial | Q46729368 |
| | The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea | Q46760336 |
| | Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy | Q46987545 |
| | Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis | Q47805850 |
| | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 |
| | Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level | Q48009616 |
| | Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. | Q50619986 |
| | Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. | Q50712240 |
| | Age and sex distributions of hematological malignancies in the U.K. | Q50868420 |
| | International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. | Q53162984 |
| | Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. | Q53979216 |
| | A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia | Q58289284 |
| | Mutation in TET2 in myeloid cancers | Q29619292 |
| | Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies | Q30773458 |
| | Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera | Q33264010 |
| | A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | Q33345998 |
| | Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. | Q33358780 |
| | Lenalidomide therapy in myelofibrosis with myeloid metaplasia | Q33370821 |
| | JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 |
| | PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia | Q33375525 |
| | Pomalidomide is active in the treatment of anemia associated with myelofibrosis | Q33385644 |
| | Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis | Q33386057 |
| | Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q33387514 |
| | Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition | Q33390073 |
| | Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q33391401 |
| | Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis | Q33391404 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | A phase-2 trial of low-dose pomalidomide in myelofibrosis | Q33392689 |
| | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 |
| | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 |
| | Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 |
| | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 |
| | The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). | Q34725589 |
| | Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents | Q35603419 |
| | Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 |
| | Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. | Q35937081 |
| | Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders | Q36311132 |
| | International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). | Q36468734 |
| | Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. | Q37289795 |
| | Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. | Q37310619 |
| | How I treat symptomatic splenomegaly in patients with myelofibrosis | Q37427166 |
| | Advances in understanding and management of myeloproliferative neoplasms | Q37445395 |
| | Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. | Q37460337 |
| | Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. | Q39977224 |
| | JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. | Q40181513 |
| | The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis | Q40265956 |
| | Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). | Q40408575 |
| | Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation | Q40659633 |
| | Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. | Q41283205 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1597-1611 | |
| P577 | publication date | 2011-04-04 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Therapeutic approaches in myelofibrosis | |
| P478 | volume | 12 | |